Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa study of EncorStat (OXB-202) for the prevention of corneal graft rejection

Trial Profile

Phase I/IIa study of EncorStat (OXB-202) for the prevention of corneal graft rejection

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Angiostatin-endostatin gene therapy Oxford BioMedica (Primary)
  • Indications Keratoplasty rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Mar 2017 According to an Oxford BioMedica media release, the company has been working on appropriate regulatory approval for the initiation of a Phase I/II clinical study in the United Kingdom.
    • 21 Feb 2014 New trial record
    • 17 Feb 2014 As confirmed on 19 November 2013, Oxford BioMedica was awarded a EUR1.8 million grant by the UK's Technology Strategy Board, which will facilitate the funding of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top